膀胱镜检查正常但细胞学或尿液标志物阳性患者的管理
本报告探讨高级别非肌层浸润性肿瘤经尿道切除成功并接受卡介苗(BCG)治疗后膀胱镜检查正常者的随访,聚焦细胞学阳性而尿液标志物阴性、或标志物阳性而细胞学阴性两种情形,讨论证据与指南推荐及哪种检测更可靠。患者摘要指出组织检查比标志物结果更可靠。
要点
- 高级别非肌层浸润性肿瘤经尿道切除并BCG治疗后膀胱镜正常者需随访。
- 细胞学与尿液标志物结果不一致时,组织检查比标志物更可靠。
- 证据与指南推荐用于处理细胞学或标志物阳性的情形。
核心结论
- 作者认为组织检查比尿液标志物结果更可靠。
研究设计与样本
- 本报告为会议报告,讨论高级别非肌层浸润性肿瘤经尿道切除成功并接受卡介苗(BCG)治疗后膀胱镜检查正常患者的随访。
主要发现
- 聚焦细胞学阳性而尿液标志物阴性、以及标志物阳性而细胞学阴性两种可能结果。
- 讨论证据与指南推荐以及哪种检测更可靠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This presentation considers follow-up after successful transurethral resection of a high-grade non-muscle-invasive tumour, with normal cystoscopy, followed by bacillus-Calmette-Guérin (BCG) therapy. Focusing on two possible outcomes, a positive cytology but a negative urinary biomarker result, versus positive biomarkers but a negative cytology, we discuss what the evidence and guidelines recommend and which test is more robust. PATIENT SUMMARY: Bladder cancer is usually assessed by examination of tissue taken from the bladder, either by surgery or by biopsy; however, trace elements in the urine, known as biomarkers, can also provide an assessment. The challenge arises when the two methods do not agree: the tissue sample is positive for cancer, but the biomarker is negative, or the reverse. For now, these authors conclude that the tissue examination is more reliable than the biomarker result.
引用
- Palou J, Brausi M, Catto JWF, et al. Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. Eur Urol Oncol. 2019. PMID: 31331861. doi:10.1016/j.euo.2019.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。